Gland Pharma Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 28, 2025. Further, the company has informed the Exchange regarding voting results.
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma held its 47th Annual General Meeting on August 28, 2025 via video conferencing, where all 7 resolutions were passed with overwhelming majority. About 89% of outstanding shares (146.6 million out of 164.76 million) participated in the voting. Shareholders approved the audited standalone and consolidated financial statements for FY25, the final dividend for FY ended March 31, 2025, reappointment of Dr. Jia Ai Zhang and Mr. Srinivas Sadu as directors, appointment of secretarial auditors, and the special resolution to re-appoint Mr. Essaji Goolam Vahanvati as Independent Director along with profit-based commission. Promoter group (with 85.39 million shares) voted 100% in favour of all resolutions. The only notable opposition came on director reappointments, with around 80,689 to 209,480 votes against the reappointment of Dr. Jia Ai Zhang and Mr. Srinivas Sadu respectively, though these still passed comfortably above 99.8% approval.
Routine procedural filing — no material surprise as all resolutions passed with near-unanimous support. Shareholders should note the final dividend declaration for FY25 is now formally confirmed via this AGM vote. Strong promoter backing and high institutional participation (~92% of public institution shares voted) signals continued confidence in management.